Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., describes AlloVaxTM as a new drug under development that combines the product AlloStimTM with a vaccine formulation containing chaperone or heat shock proteins isolated from a piece of a patient's tumor. This vaccine may be used in patients with hematological malignancies that are eligible for first-line chemotherapy and radiation. Dr. Michael Har-Noy notes that most patients with these cancers will achieve remission with conventional radiation and chemotherapy, but almost all will subsequently suffer a relapse. Allogeneic bone marrow transplant is the only curative procedure left for these patients, but the high toxicity associated with this procedure and the need for a matched donor limits its use.
Dr. Michael Har-Noy goes on to explain that AlloVaxTM is individualized anti-tumor vaccine that educates the patient's immune system during the period of remission to prevent the cancer from returning. Chaperone proteins isolated from malignant cells have been shown to carry tumor antigens that may be used to train a patient's immune system to recognize and kill the cancer cells they came from. Immunovative Therapies has acquired the exclusive rights to use a patented method developed by Dr. Emmanuel Katsanis at the University of Arizona to isolate these chaperone proteins from tumor tissue.
To start the AlloVaxTM protocol, tumor cells are removed from the patient prior conventional treatment. When the patient achieves remission, intradermal injections of Dr. Michael Har-Noy's AlloStimTM compound are given. The AlloStimTM is rejected by the patient's immune system, thereby making the patient immune to the AlloStimTM cells. Chaperone proteins containing the unique tumor antigens are then processed from the patient's cancer cells that were sampled prior to radiation and/or chemotherapy. These chaperone proteins are then injected intradermally along with the AlloStimTM. Dr. Michael Har-Noy notes that AlloStimTM helps stimulate chaperone protein vaccine formulation, thereby causing an immune response to reject the AlloStimTM and a simultaneous response against the unique tumor antigens carried by the chaperone proteins. Dr. Michael Har-Noy indicates that the powerful combination of these two responses educates the host immune system that the tumor antigens are dangerous. Therefore, if the cancer recurs, the patient's immune system is ready to kill the tumor cells and keep the patient in remission.